Submit U.S. application for Mavacamten for obstructive HCM
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Mavacamten U.S. submission for obstructive HCM planned Q1 2021”
What we found
Evidence strength A What the grades mean
The company announced in March 2021 that the FDA had accepted the New Drug Application (NDA) for mavacamten, confirming the submission occurred within the Q1 2021 timeframe.
-
A Bristol Myers Squibb Co. 10-Q filed 2021-04-29
“March 2021Announced that the FDA accepted the NDA for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin, for patients with symptomatic obstructive hypertrophic cardiomyopathy.” ✓ confirmed on the page
Market reaction: the shares moved -4.0% against the S&P 500 over the three sessions around the disclosure (28 Apr 2021 to 3 May 2021). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- U.S. application for Mavacamten
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BMY-003995 · Corrections policy